Longevity & AgingPress Release

FDA Rejects Ivonescimab for EGFR-Mutant Lung Cancer After Trial Misses Survival Goal

The FDA declined to approve ivonescimab for pretreated EGFR-mutant lung cancer because progression-free survival gains did not come with a significant overall survival benefit.

Tuesday, November 17, 2026 0 views
Published in MedPage Today
Article visualization: FDA Rejects Ivonescimab for EGFR-Mutant Lung Cancer After Trial Misses Survival Goal

Summary

The FDA has declined to approve ivonescimab, a bispecific antibody that blocks both PD-1 and VEGF, for previously treated EGFR-mutant non-small cell lung cancer. The decision rests on the phase III HARMONi trial. Adding the drug to platinum chemotherapy slowed disease progression, with median progression-free survival of 6.8 months versus 4.4 months on placebo. Overall survival was longer on paper, 16.8 versus 14 months, but the difference did not reach statistical significance. The FDA concluded that a progression-free survival gain without a clear survival benefit does not support a positive benefit-risk profile. The benefit also looked larger in Asian patients than in North American and European patients. The drug is approved in China, and other trials in Asian and global populations are still underway, so further chances at US approval remain.

Detailed Summary

Lung cancer remains one of the deadliest cancers, and EGFR-mutant disease is a hard subset to treat once targeted pills stop working. New drugs for these patients matter, and so do the standards regulators use to judge them. The FDA's decision on ivonescimab shows how high that bar is.

Ivonescimab is a bispecific antibody that blocks PD-1, an immune checkpoint, and VEGF, a driver of tumor blood vessel growth. In the phase III HARMONi trial, patients had progressed on third-generation EGFR tyrosine kinase inhibitors. They received platinum chemotherapy with either ivonescimab or placebo. Median progression-free survival was 6.8 months with ivonescimab versus 4.4 months with placebo (HR 0.52, P<0.0001). Median overall survival was 16.8 versus 14 months (HR 0.79, 95% CI 0.62-1.01, P=0.057), which missed statistical significance.

The FDA issued a complete response letter. It said that progression-free survival benefit without a significant overall survival benefit does not support a positive benefit-risk profile. The progression-free survival benefit was also greater in Asian patients than in the North American and European subset, which raises questions about how well the results apply across populations.

The drug is not finished in the US. It is approved for several lung cancer indications in China. HARMONi-6 showed an overall survival gain in an all-Asian squamous population, and HARMONi-2 showed one against pembrolizumab in Chinese patients. HARMONi-3 and HARMONi-7 are testing it in global and PD-L1-high populations, and it is also being studied in colorectal, urothelial and renal cell cancers.

For patients and clinicians, this is a regulatory setback, not a final verdict. Caveats: this is a brief news report based largely on the sponsor's press release. The overall survival result was borderline, and the full trial data, safety profile and subgroup analyses should be reviewed in peer-reviewed publications.

Key Findings

  • FDA issued a complete response letter for ivonescimab in previously treated EGFR-mutant NSCLC.
  • HARMONi median PFS was 6.8 vs 4.4 months with placebo (HR 0.52).
  • Median OS was 16.8 vs 14 months, not significant (HR 0.79, P=0.057).
  • PFS benefit was larger in Asian patients than in North American/European patients.
  • HARMONi-3 and HARMONi-7 could still support future US approval in first-line NSCLC.

Methodology

This is a short news report from MedPage Today, drawing on a Summit Therapeutics press release and published trial data. The underlying evidence is a randomized phase III trial, but the article is a secondary summary.

Study Limitations

The article relies heavily on company statements and does not detail safety or quality-of-life data. The overall survival result was borderline and the regional differences are not fully explained. Verify details in the peer-reviewed trial publications and the FDA letter.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: